Cargando…
Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination
SARS-CoV-2 variants of concern (VOCs) can trigger severe endemic waves and vaccine breakthrough infections (VBI). We analyzed the cellular and humoral immune response in 8 patients infected with the alpha variant, resulting in moderate to fatal COVID-19 disease manifestation, after double mRNA-based...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821964/ https://www.ncbi.nlm.nih.gov/pubmed/35145522 http://dx.doi.org/10.3389/fimmu.2022.816220 |
_version_ | 1784646507357536256 |
---|---|
author | Paniskaki, Krystallenia Anft, Moritz Meister, Toni L. Marheinecke, Corinna Pfaender, Stephanie Skrzypczyk, Sarah Seibert, Felix S. Thieme, Constantin J. Konik, Margarethe J. Dolff, Sebastian Anastasiou, Olympia Holzer, Bodo Dittmer, Ulf Queren, Christine Fricke, Lutz Rohn, Hana Westhoff, Timm H. Witzke, Oliver Stervbo, Ulrik Roch, Toralf Babel, Nina |
author_facet | Paniskaki, Krystallenia Anft, Moritz Meister, Toni L. Marheinecke, Corinna Pfaender, Stephanie Skrzypczyk, Sarah Seibert, Felix S. Thieme, Constantin J. Konik, Margarethe J. Dolff, Sebastian Anastasiou, Olympia Holzer, Bodo Dittmer, Ulf Queren, Christine Fricke, Lutz Rohn, Hana Westhoff, Timm H. Witzke, Oliver Stervbo, Ulrik Roch, Toralf Babel, Nina |
author_sort | Paniskaki, Krystallenia |
collection | PubMed |
description | SARS-CoV-2 variants of concern (VOCs) can trigger severe endemic waves and vaccine breakthrough infections (VBI). We analyzed the cellular and humoral immune response in 8 patients infected with the alpha variant, resulting in moderate to fatal COVID-19 disease manifestation, after double mRNA-based anti-SARS-CoV-2 vaccination. In contrast to the uninfected vaccinated control cohort, the diseased individuals had no detectable high-avidity spike (S)-reactive CD4+ and CD8+ T cells against the alpha variant and wild type (WT) at disease onset, whereas a robust CD4+ T-cell response against the N- and M-proteins was generated. Furthermore, a delayed alpha S-reactive high-avidity CD4+ T-cell response was mounted during disease progression. Compared to the vaccinated control donors, these patients also had lower neutralizing antibody titers against the alpha variant at disease onset. The delayed development of alpha S-specific cellular and humoral immunity upon VBI indicates reduced immunogenicity against the S-protein of the alpha VOC, while there was a higher and earlier N- and M-reactive T-cell response. Our findings do not undermine the current vaccination strategies but underline a potential need for the inclusion of VBI patients in alternative vaccination strategies and additional antigenic targets in next-generation SARS-CoV-2 vaccines. |
format | Online Article Text |
id | pubmed-8821964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88219642022-02-09 Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination Paniskaki, Krystallenia Anft, Moritz Meister, Toni L. Marheinecke, Corinna Pfaender, Stephanie Skrzypczyk, Sarah Seibert, Felix S. Thieme, Constantin J. Konik, Margarethe J. Dolff, Sebastian Anastasiou, Olympia Holzer, Bodo Dittmer, Ulf Queren, Christine Fricke, Lutz Rohn, Hana Westhoff, Timm H. Witzke, Oliver Stervbo, Ulrik Roch, Toralf Babel, Nina Front Immunol Immunology SARS-CoV-2 variants of concern (VOCs) can trigger severe endemic waves and vaccine breakthrough infections (VBI). We analyzed the cellular and humoral immune response in 8 patients infected with the alpha variant, resulting in moderate to fatal COVID-19 disease manifestation, after double mRNA-based anti-SARS-CoV-2 vaccination. In contrast to the uninfected vaccinated control cohort, the diseased individuals had no detectable high-avidity spike (S)-reactive CD4+ and CD8+ T cells against the alpha variant and wild type (WT) at disease onset, whereas a robust CD4+ T-cell response against the N- and M-proteins was generated. Furthermore, a delayed alpha S-reactive high-avidity CD4+ T-cell response was mounted during disease progression. Compared to the vaccinated control donors, these patients also had lower neutralizing antibody titers against the alpha variant at disease onset. The delayed development of alpha S-specific cellular and humoral immunity upon VBI indicates reduced immunogenicity against the S-protein of the alpha VOC, while there was a higher and earlier N- and M-reactive T-cell response. Our findings do not undermine the current vaccination strategies but underline a potential need for the inclusion of VBI patients in alternative vaccination strategies and additional antigenic targets in next-generation SARS-CoV-2 vaccines. Frontiers Media S.A. 2022-01-25 /pmc/articles/PMC8821964/ /pubmed/35145522 http://dx.doi.org/10.3389/fimmu.2022.816220 Text en Copyright © 2022 Paniskaki, Anft, Meister, Marheinecke, Pfaender, Skrzypczyk, Seibert, Thieme, Konik, Dolff, Anastasiou, Holzer, Dittmer, Queren, Fricke, Rohn, Westhoff, Witzke, Stervbo, Roch and Babel https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Paniskaki, Krystallenia Anft, Moritz Meister, Toni L. Marheinecke, Corinna Pfaender, Stephanie Skrzypczyk, Sarah Seibert, Felix S. Thieme, Constantin J. Konik, Margarethe J. Dolff, Sebastian Anastasiou, Olympia Holzer, Bodo Dittmer, Ulf Queren, Christine Fricke, Lutz Rohn, Hana Westhoff, Timm H. Witzke, Oliver Stervbo, Ulrik Roch, Toralf Babel, Nina Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination |
title | Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination |
title_full | Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination |
title_fullStr | Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination |
title_full_unstemmed | Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination |
title_short | Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination |
title_sort | immune response in moderate to critical breakthrough covid-19 infection after mrna vaccination |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821964/ https://www.ncbi.nlm.nih.gov/pubmed/35145522 http://dx.doi.org/10.3389/fimmu.2022.816220 |
work_keys_str_mv | AT paniskakikrystallenia immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT anftmoritz immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT meistertonil immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT marheineckecorinna immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT pfaenderstephanie immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT skrzypczyksarah immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT seibertfelixs immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT thiemeconstantinj immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT konikmargarethej immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT dolffsebastian immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT anastasiouolympia immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT holzerbodo immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT dittmerulf immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT querenchristine immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT frickelutz immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT rohnhana immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT westhofftimmh immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT witzkeoliver immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT stervboulrik immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT rochtoralf immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination AT babelnina immuneresponseinmoderatetocriticalbreakthroughcovid19infectionaftermrnavaccination |